Latest Intelligence in Switzerland

Published within

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

Licensing Week - August 16, 2002

Last week's licensing news had a truly global feel, with companies from the US, the UK, mainland Europe and Japan getting in on the action. The week saw deals between; AstraZeneca and Xenogen; Crucell and GenVec; Takeda and Human Genome Sciences; Adolor and Eli Lilly; and Anadys and Roche.

Published By Datamonitor
15 Aug 2002
Expert View
Expert View

Licensing Week - August 9, 2002

Last week saw a flurry of licensing activity by Bristol-Myers Squibb, as the US-based big pharma extended its drug discovery relationships with Athersys and Exelixis. Genomics also featured heavily last week, as Pfizer, Oxagen, Fujisawa and Quark were all involved in genetic research deals. Finally, Serono signed another marketing deal, this time licensing rights to Genentech's Raptiva.<BR />

Published By Datamonitor
08 Aug 2002
CommentWire
CommentWire

Lindt & Spruengli: premium positioning driving sales growth

A 14% rise in sales is expected to be announced by Lindt & Spruengli on January 22, 2008, along with organic growth of between 6% and 8%. The Swiss chocolate company has continued to grow sales, despite growing consumer interest in adopting healthier lifestyles. Lindt's success can, in part, be attributed to its premium positioning, but it will, however, face fresh challenges in 2008.

Published By Datamonitor
21 Jan 2008
CommentWire
CommentWire

Lindt & Sprungli: premium paying off

Profits at Lindt & Sprungli, the prestige Swiss maker of Lindor and Ghirardelli chocolates, reached new highs on the back of consumers' increasing penchant for luxury treats. However the growing push to premium in many developed markets may bring with it the competitive threat of mass market rivals muscling in on Lindt's territory.

Published By Datamonitor
16 Mar 2005
CommentWire
CommentWire

Lindt: a little luxury makes all the difference

Published By Datamonitor
28 Mar 2001
Expert View
Expert View

Lloyds Banking Group calling time on Switzerland

Lloyds Banking Group's decision to sell its international private banking business and refocus on the UK comes as no great revelation. However, the inclusion of its Swiss business in the sale is more of a surprise.

Published By Datamonitor
31 May 2013
CommentWire
CommentWire

Luxury goods industry: future's looking good

Luxury goods manufacturers have been reporting mixed results for H1 2002 sales; the slow economy and the continuing weakness in tourism have impacted growth. However, industry players can feel optimistic about the steady growth in the number and value of mass affluent and high net worth consumers, which will provide a sound base to develop and grow the prestige market.

Published By Datamonitor
12 Sep 2002
CommentWire
CommentWire

Merck KGaA: good news finally for Erbitux

Swiss regulators have recommended the approval of Merck KGaA's [MRK.F] Erbitux as a second-line therapy for colorectal cancer. The drug is set to be approved within 30 days and Switzerland will be the first market to approve the drug. Given Erbitux's past difficulties, it is welcome news, not only for Merck, but also for ImClone [IMCL] and BMS [BMY].

Published By Datamonitor
17 Nov 2003
CommentWire
CommentWire

Mirabaud: going for Monaco's grand prix

Mirabaud has received approval to launch a wealth and asset management business for private clients in Monaco. The new company represents a promising venture and, in following the management philosophy of its parent, should be able to cash in on three decades of valuable experience catering for the high net worth segment.

Published By Datamonitor
16 Jun 2005
ResearchWire
ResearchWire

Mutual funds: Swiss market growth slashed

Published By Datamonitor
04 May 2001

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

No help is available.